According to the World Health Organization (WHO), depression and anxiety disorders, including stress-related psychiatric conditions, would rival cardiovascular diseases by 2020 as the major health disorder with the highest disease burden globally. Antidepressants and anxiolytics are the medications used to treat various types of depression and anxiety disorders and prevent them from recurring. Anxiety is a natural reaction to stress, trauma and fear, which can be experienced by everyone at times. However, when this condition becomes severe, it might challenge an individual’s capability to lead a normal life. Similarly, depression is a state of low mood and aversion to daily activities that can affect an individual’s feelings, thoughts, sense of well-being and behavior. Various researches reveal that anxiety disorders and depression are the major risk factors for suicide among humans. Over 90% of individuals who commit suicide have some sort of diagnosable mental illness. It has also been reported that depression and anxiety disorders are more prevalent in developed economies such as the U.S., Canada, France, Germany, the U.K., and Italy due to the high levels of work-associated stress, personal relationships, societal factors, environmental factors as well as genetic aspects prevalent in these geographies.
Presently, the global anxiety disorders and depression treatment market is on a decline due to patent expiry of major antidepressants, weak pipeline of novel drugs and increasing number of generic drug variants. However, driving factors such as increasing prevalence of anxiety disorders and depression and rising geriatric population prone to psychiatric disorders are expected to offset the declining growth of the market in the near future.
The anxiety disorders and depression treatment market has been segmented based on drug classes most commonly used for the treatment and prevention of psychiatric disorders. Based on drug classes, the market has been segmented into selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCA), monoamine oxidase inhibitors (MAOIs), benzodiazepines, atypical antipsychotics, anticonvulsants and beta blockers. SNRIs accounted for the largest share of the depression treatment market in 2013. However, the segment is expected to witness a decline in revenue during the forecast period. Patent expirations of leading branded formulations such as Cymbalta and Effexor XR coupled with growing influx of generic formulations are some of the major factors expected to affect the growth of the segment. Similarly, SSRIs accounted for the largest share of the anxiety disorders treatment market in 2013. However, the market for SSRIs is expected to decline due to patent expirations, growing prevalence of treatment-resistant psychiatric disorders and high adoption rate of generic drugs.
North America is the largest market for anxiety disorders and depression treatment drugs due the presence of large patient population suffering from various types of anxiety disorders and depression. However, the anxiety disorders and depression treatment market in the U.S. is currently saturated, as several antidepressant drugs are available on prescription for the same indication. Hence, the future growth of the market would depend on introduction of efficacious drugs for new indications. Moreover, loss of patent exclusivity, market maturity, generic infiltration and shortened drug lifecycles are the additional factors that contribute to the decline in market growth in the region. Asia Pacific is expected to witness an appreciable growth due to multiple factors such as high prevalence of psychiatric disorders and rapid economic growth in countries such as China, Japan and Australia. Additionally, positive marketing approval for innovative medicines is likely to drive the market in the near future.
Currently, the market is highly fragmented and competitive in nature due to the involvement of both large and small pharmaceutical companies. AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline plc, H. Lundbeck A/S, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Sanofi S.A. are major companies operating in the anxiety disorders and depression treatment market. Majority of the market players are focusing on expanding distribution network as well as expanding geographical presence, as Asia Pacific, the Middle East, and Latin America are developing regions with an increasing prevalence of various types of anxiety disorders and depression and improving economic conditions.
Anxiety disorders and depression are common psychiatric disorders that affect a large number of people during their lifetime. This study provides the market analysis for the major drug classes used for the treatment of anxiety disorders and depression. The stakeholders of this report include established pharmaceutical companies as well as new entrants who wish to enter the market.
The market overview chapter, which has been provided in the study, analyzes the current market dynamics and other trends such as drivers, restraints, opportunities that would govern the present and future circumstances of the anxiety disorder and depression treatment market. Furthermore, Porter’s five forces analysis has been incorporated in this research to provide the competitive status of the anxiety disorders and depression treatment market; and market attractiveness analysis has been included to describe the market position across various geographies. Event impact analysis has been provided in this report for better understanding the significant events that have taken place in the past and are planned for the future and which might have a major impact on industry growth. Regulatory framework has also been discussed in this section to provide an overall idea about the regulatory scenario across the major geographies.
This research on anxiety disorders and depression treatment has been categorized based on various classes of drugs that are generally used for the treatment of these psychiatric conditions. Various drug classes considered while estimating the overall market are selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCAs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), benzodiazepines, beta-blockers, atypical antipsychotics and anticonvulsants. The market for these drug classes has been comprehensively analyzed based on the expiry, launch, sales revenue, efficacy and geographic presence of leading drugs in each of the classes mentioned above. Market revenue (USD million) for each of these drug classes has been provided in the research for the period 2012 to 2020 in terms of USD million, with CAGR for the forecast period 2014 to 2020, taking into account 2013 as the base year.
In terms of geography, the global anxiety disorders and depression treatment market has been categorized into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). In the geography section of the report, the market revenue (USD million) of various drug classes used for the treatment of anxiety disorders and depression for each of these geographic regions for 2012 and 2020 along with forecast period from 2014 to 2020 has been provided and explained in detail.
The chapter on competitive landscape included in the report provides a detailed market share analysis of the major leading companies in the anxiety disorders and depression treatment market, in terms of percentage share for the year 2013. The detailed market share analysis of the industry participants involved in the market would help new organizations to identify the product portfolio of established global players and understand the business plans followed by key companies for sustaining in the market. Several pointers on strategic recommendations have also been provided for new industry participants as well as established organizations to help in securing a strong position in the global market and improve market share. Furthermore, the research comprises a chapter on pipeline analysis for this industry that includes sales forecast for recently launched drugs and potential drugs that are undergoing phase III clinical trials and are expected to be marketed during the forecast period.
The report provides in-depth company profiles of major players in the anxiety disorders and depression treatment market based on a variety of characteristics such as company overview, financial overview, product portfolio, business strategies and recent developments. Major players profiled in this study include AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline plc, H. Lundbeck A/S, Pfizer, Inc., Merck & Co., Inc. and Sanofi S.A.
The global anxiety disorders and depression treatment market is segmented as follows:
Anxiety Disorders and Depression Treatment Market, by Drug Class
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Atypical Antipsychotics
- Tricyclic Antidepressants (TCAs)
- Tetracyclic Antidepressants (TeCAs)
- Monoamine Oxidase inhibitors (MAOIs)
Anxiety Disorders and Depression Treatment Market, by Geography
- North America
- Rest of the World (RoW)